Vol. 15, No. 4, 2006
Issue release date: June 2006
Open Access Gateway
Med Princ Pract 2006;15:245–252
(DOI:10.1159/000092985)
Review Article
Add to my selection

Intraductal Papillary Mucinous Neoplasms of the Pancreas

Al-Refaie W.B. · Choi E.A. · Tseng J.F. · Tamm E.P. · Lee J.H. · Lee J.E. · Evans D.B. · Pisters P.W.T.
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Tex., USA
email Corresponding Author


 goto top of outline Key Words

  • Intraductal papillary mucinous neoplasms
  • Pancreas
  • Pancreatic neoplasms

 goto top of outline Abstract

The introduction of the exocrine pancreatic classification by the World Health Organization and improvements in pancreatic imaging have led to an improved understanding of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. As a result, IPMNs of the pancreas are increasingly being recognized as a separate disease entity. IPMNs are characterized by the cystic dilatation of the pancreatic duct and its branches, with papillary projections. There are three histological subtypes of IPMNs: main duct, branch duct, and mixed. The degree of atypia ranges from adenoma to frank invasive carcinoma. The lymph nodes are involved considerably less frequently than they are in pancreatic adenocarcinoma. Most patients are symptomatic at diagnosis and require a diagnostic workup similar to that for patients with pancreatic adenocarcinoma. Although some investigators continue to advocate total pancreatectomy, the evidence in support of this is decreasing. Partial pancreatectomy remains the treatment option. Intraoperative assessment of the resection surgical margins is an important component of surgical resection. Additionally, controversy also exists regarding the nature of the follow-up and the need for adjuvant chemoradiation therapy in the patient. Unlike ductal adenocarcinomas, IPMNs follow a relatively indolent course; the 5-year survival rate in patients with invasive IPMNs is 57%. A mural nodule and a main pancreatic duct diameter greater than 5 mm have been found to be predictors of malignancy.

Copyright © 2006 S. Karger AG, Basel


 goto top of outline References
  1. Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH: Histological Typing of Tumours of the Exocrine Pancreas, 2nd ed. Berlin, Springer, 1998.
  2. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004;239:678–685.
  3. Ohashi K, Murakami Y, Maruyama M: Four cases of mucin-producing cancer of the pancreas on specific findings of the papilla of Vater (in Japanese). Prog Dig Endosc 1982;20:348–351.
  4. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244–1249.
  5. D’Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC: Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004;239:400–408.
  6. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788–797.
  7. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD: Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001;234:313–321.
  8. Jang J, Kim S, Ahn YJ, Yoon Y, Choi M, Lee K, Han J, Kim W, Lee YJ, Kim SC, Han DJ, Kim YI, Choi SH, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee KB, Kim YC, Lee KS, Kim M, Kim HJ, Kim HJ, Park Y: Multicenter analysis of clinicopathologic features of Intraductal papillary mucinous tumors of the pancreas: is it possible to predict malignancy before surgery? Ann Surg Oncol 2005;12:124–132.
  9. Maire F, Couvelard A, Hammel P, Ponsot P, Palazzo L, Aubert A, Degott C, Dancour A, Felce-Dachez M, O’Toole D, Levy P, Ruszniewski P: Intraductal papillary mucinous tumors of the pancreas: the preoperative value of cytologic and histopathologic diagnosis. Gastrointest Endosc 2003;58:701–716.
  10. Adsay NV: Intraductal papillary mucinous neoplasms of the pancreas: pathology and molecular genetics. J Gastrointest Surg 2002;6:656–659.
  11. Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS: Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer 2002;94:62–77.
  12. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Kloppel G, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Shimizu M, Yonezawa S: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:977–987.
  13. Schmitz-Winnenthal FH, Z’Graggen K, Volk C, Schmied BM, Buchler MW: Intraductal papillary mucinous tumors of the pancreas. Curr Gastroenterol Rep 2003;5:133–140.
  14. Yonezawa S, Horinouchi M, Osako M, Kubo M, Takao S, Arimura Y, Nagata K, Tanaka S, Sakoda K, Aikou T, Sato E: Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int 1999;49:45–54.
  15. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002–2006.
  16. Wiesenauer CA, Schmidt CM, Cummings OW, Yiannoutsos CT, Howard TJ, Wiebke EA, Goulet RJ Jr, McHenry L, Sherman S, Lehman GA, Cramer H, Madura JA: Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms. Arch Surg 2003;138:610–617.
  17. Tanaka M: Intraductal papillary mucinous neoplasm of the pancreas: diagnosis and treatment. Pancreas 2004;28:282–288.
  18. Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, Hama T, Yamaue H: Clinicopathological features of malignant intraductal papillary mucinous tumors of the pancreas: the differential diagnosis from benign entities. Arch Surg 2004;139:188–192.
  19. Conlon KC: Intraductal papillary mucinous tumors of the pancreas. J Clin Oncol 2005;23:4518–4523.
  20. Sauvanet A, Partensky C, Sastre B, Gigot JF, Fagniez PL, Tuech JJ, Millat B, Berdah S, Dousset B, Jaeck D, Le Treut YP, Letoublon C: Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club. Surgery 2002;132:836–843.
  21. Ozaki H, Kinoshita T, Kosuge T, Shimada K, Yamamoto J, Inoue K: Selection of methods for diagnosis and treatment of pancreatic cancer (in Japanese). Gan To Kagaku Ryoho 1992;19:2311–2318.
  22. Kanazumi N, Nakao A, Kaneko T, Takeda S, Harada A, Inoue S, Nagasaka T, Nakashima N: Surgical treatment of intraductal papillary-mucinous tumors of the pancreas. Hepatogastroenterology 2001;48:967–971.
  23. Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW, Fernandez-del Castillo C: Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg 2005;242:413–419; discussion 419–421.
  24. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, Lee JE, Evans DB, Pisters PW: Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005;140:584–958; discussion 589–591.
  25. Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, Barthet M, O’Toole D, Rufat P, Partensky C, Cuillerier E, Levy P, Belghiti J, Ruszniewski P: Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection: comparison with pancreatic ductal adenocarcinoma. Gut 2002;51:717–722.
  26. Wada K, Kozarek RA, William Traverso L: Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg 2005;189:632–636.
  27. Tanaka M CS, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno M: International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas. Pancreatology 2005;6:17–32.

    External Resources

  28. Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, Bernades P, Belghiti J, Ruszniewski P, Flejou JF: Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–1377.
  29. Nakagohri T, Kenmochi T, Kainuma O, Tokoro Y, Asano T: Intraductal papillary mucinous tumors of the pancreas. Am J Surg 1999;178:344–347.

 goto top of outline Author Contacts

Peter W.T. Pisters, MD
Department of Surgical Oncology, Unit 444
The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard
Houston, TX 77230-1402 (USA)
Tel. +1 713 794 1572, Fax +1 713 792 7829, E-Mail ppisters@mdanderson.org


 goto top of outline Article Information

Received: August 22, 2005
Revised: January 22, 2006
Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 1, Number of References : 29


 goto top of outline Publication Details

Medical Principles and Practice (International Journal of the Kuwait University Health Sciences Centre)

Vol. 15, No. 4, Year 2006 (Cover Date: June 2006)

Journal Editor: Al-Zaid, N.S. (Kuwait)
ISSN: 1011–7571 (print), 1423–0151 (Online)

For additional information: http://www.karger.com/MPP


Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.